(Q30616602)

25 June 2017

title

Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors (English)

1 reference

25 June 2017

1 reference

1 reference

Yoshitaka Narita

1

1 reference

25 June 2017

language of work or name

1 reference

12 April 2013

1 reference

Japanese Journal of Clinical Oncology

25 June 2017

published in

1 reference

25 June 2017

volume

43

1 reference

25 June 2017

issue

6

1 reference

25 June 2017

page(s)

587-595

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

25 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Treatment with bevacizumab plus carboplatin for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab and daily temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab in recurrent high-grade pediatric gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Rechallenge with temozolomide in patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Strategy of surgery and radiation therapy for brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Effect of bevacizumab on radiation necrosis of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Exacerbation of cerebral radiation necrosis by bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab as a treatment option for radiation-induced cerebral necrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab reverses cerebral radiation necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

A novel tool to analyze MRI recurrence patterns in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Hypofractionated reirradiation for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

The role of salvage reirradiation for malignant gliomas that progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Irradiation and bevacizumab in high-grade glioma retreatment settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Management of hypertension in angiogenesis inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

VEGF inhibition and renal thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab increases risk for severe proteinuria in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Intracranial hemorrhage in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Bevacizumab safety in patients with central nervous system metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Ischemic stroke in patients with primary brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Venous thromboembolism and survival in patients with high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Safety of anticoagulation use and bevacizumab in patients with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Reversible posterior leukoencephalopathy syndrome and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

A review on bevacizumab and surgical wound healing: an important warning to all surgeons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

Impact of bevacizumab chemotherapy on craniotomy wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT051

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYT051

1 reference

25 June 2017

1 reference